XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.
The Pharma Data
NOVEMBER 5, 2020
About Jubilant Cadista Pharmaceuticals Inc. Jubilant Cadista Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company in the United States devoted to discovery, manufacture, sale, and distribution of prescription generic pharmaceutical products. About Jubilant Pharma Limited.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 22, 2022
The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth. Blueprint Medicines wins the Financing award this year after securing significant financing partnerships worth up to $1.25bn.
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.
XTalks
JUNE 8, 2022
Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.
XTalks
AUGUST 2, 2023
With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. 21) Merck KGaA By: Ayesha Rashid, Ph.D.
Pharma in Brief
DECEMBER 3, 2023
The Regulations became a moving target for the innovative and generic pharmaceutical industries, being amended seven times between 1998 and 2016. This was often the innovator’s only recourse as innovators were typically unable to appeal unfavourable judgments under the Regulations. Frequent amendments (1998–2016).
Expert insights. Personalized for you.
98 
Let's personalize your content